Loyau Jérémy, Malinge Pauline, Daubeuf Bruno, Shang Limin, Elson Greg, Kosco-Vilbois Marie, Fischer Nicolas, Rousseau François
a NovImmune SA; Plan-les-Ouates , Switzerland.
MAbs. 2014;6(6):1621-30. doi: 10.4161/19420862.2014.975098.
In order to treat Toll like receptor 4 (TLR4)-mediated diseases, we generated a potent antagonistic antibody directed against human TLR4, Hu 15C1. This antibody's potency can be modulated by engaging not only TLR4 but also Fcγ receptors (FcγR), a mechanism that is driven by avidity and not cell signaling. Here, using various formats of the antibody, we further dissect the relative contributions of the Fv and Fc portions of Hu 15C1, discovering that the relationship to potency of the different antibody arms is not linear. First, as could be anticipated, we observed that Hu 15C1 co-engages up to 3 receptors on the same plasma membrane, i.e., 2 TLR4 molecules (via its variable regions) and either FcγRI or FcγRIIA (via the Fc). The Kd of these interactions are in the nM range (3 nM of the Fv for TLR4 and 47 nM of the Fc for FcγRI). However, unexpectedly, neutralization experiments revealed that, due to the low level of cell surface TLR4 expression, the avidity afforded by engagement through 2 Fv arms was significantly limited. In contrast, the antibody's neutralization capacity increases by 3 logs when able to exploit Fc-FcγR interactions. Taken together, these results demonstrate an unforeseen level of contribution by FcγRs to an antibody's effectiveness when targeting a cell surface protein of relatively low abundance. These findings highlight an exploitable mechanism by which FcγR-bearing cells may be more powerfully targeted, envisioned to be broadly applicable to other reagents aimed at neutralizing cell surface targets on cells co-expressing FcγRs.
为了治疗Toll样受体4(TLR4)介导的疾病,我们制备了一种针对人TLR4的强效拮抗抗体Hu 15C1。该抗体的效力不仅可以通过与TLR4结合来调节,还可以通过与Fcγ受体(FcγR)结合来调节,这一机制是由亲和力而非细胞信号驱动的。在这里,我们使用不同形式的抗体,进一步剖析了Hu 15C1的Fv和Fc部分的相对贡献,发现不同抗体臂与效力之间的关系不是线性的。首先,正如预期的那样,我们观察到Hu 15C1在同一质膜上可同时结合多达3种受体,即2个TLR4分子(通过其可变区)和FcγRI或FcγRIIA(通过Fc)。这些相互作用的解离常数(Kd)在纳摩尔范围内(Fv与TLR4结合的Kd为3 nM,Fc与FcγRI结合的Kd为47 nM)。然而,出乎意料的是,中和实验表明,由于细胞表面TLR4表达水平较低,通过2个Fv臂结合所提供的亲和力受到显著限制。相比之下,当能够利用Fc-FcγR相互作用时,该抗体的中和能力增加了3个对数级。综上所述,这些结果表明,当靶向相对低丰度的细胞表面蛋白时,FcγR对抗体有效性的贡献达到了一个意想不到的水平。这些发现突出了一种可利用的机制,通过该机制可以更有效地靶向携带FcγR的细胞,预计该机制可广泛应用于其他旨在中和共表达FcγR的细胞上的细胞表面靶点的试剂。